Gilead Sciences Company Profile (NASDAQ:GILD)

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:GILD
  • CUSIP: 37555810
  • Web: www.gilead.com
Capitalization:
  • Market Cap: $95.93996 billion
  • Outstanding Shares: 1,306,728,000
Average Prices:
  • 50 Day Moving Avg: $68.32
  • 200 Day Moving Avg: $68.63
  • 52 Week Range: $63.76 - $88.85
P/E:
  • Trailing P/E Ratio: 7.80
  • Foreward P/E Ratio: 10.27
  • P/E Growth: -1.04
Sales & Book Value:
  • Annual Revenue: $29.1 billion
  • Price / Sales: 3.31
  • Book Value: $15.64 per share
  • Price / Book: 4.72
Dividend:
  • Annual Dividend: $2.08
  • Dividend Yield: 2.8%
Profitability:
  • EBIDTA: $18.24 billion
  • Net Margins: 43.42%
  • Return on Equity: 76.64%
  • Return on Assets: 25.55%
Debt:
  • Debt-to-Equity Ratio: 1.26%
  • Current Ratio: 2.59%
  • Quick Ratio: 2.41%
Misc:
  • Average Volume: 8.63 million shs.
  • Beta: 1.21
  • Short Ratio: 1.45
 
Frequently Asked Questions for Gilead Sciences (NASDAQ:GILD)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Tuesday, May 2nd. Shareholders of record on Friday, June 16th will be given a dividend of $0.52 per share on Thursday, June 29th. This represents a $2.08 annualized dividend and a yield of 2.82%. The ex-dividend date of this dividend is Wednesday, June 14th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings results on Tuesday, May, 2nd. The company reported $2.20 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.18 by $0.02. The company had revenue of $6.51 billion for the quarter, compared to analysts' expectations of $6.66 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. View Gilead Sciences' Earnings History.

Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2017?

26 brokers have issued 12-month target prices for Gilead Sciences' shares. Their forecasts range from $65.50 to $95.00. On average, they anticipate Gilead Sciences' stock price to reach $80.32 in the next twelve months. View Analyst Ratings for Gilead Sciences.

What are analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

  • 1. According to Zacks Investment Research, "Gilead’s HIV franchise has been gaining momentum of late. Rapid adoption of TAF-based regimens, representing 42% of total Gilead HIV prescription volume, following the launch of Genvoya and the launches of Odefsey and Descovy in 2016 boosted results. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales.The company saw a significant uptick in PrEP usage in 2017 with an estimated 125,000 patients using Truvada by the end of the first quarter. The company submitted a NDA to the FDA for single tablet regimen for bictegravir. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. In addition, the HCV franchise continues to be under competitive and pricing pressure leading to a decline in Harvoni and Sovaldi sales." (7/18/2017)
  • 2. Maxim Group analysts commented, "Gilead reported 1Q17 results with total revenues of $6.5B, which just missed consensus expectations. Total revenues declined by 11% compared to the prior quarter’s revenues of $7.2B, and product sales were $6.4B, representing a 12% decrease sequentially. HCV product reveneues fell to $2.6B vs. $3.2B in 4Q16, down 20% as a result of declining revenues for Harvoni ($1.4B), Sovaldi ($313M), and Epclusa ($892M)." (5/3/2017)
  • 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)
  • 4. Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)

Are investors shorting Gilead Sciences?

Gilead Sciences saw a increase in short interest in June. As of June 30th, there was short interest totalling 13,658,785 shares, an increase of 15.7% from the June 15th total of 11,804,652 shares. Based on an average daily trading volume, of 13,707,757 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.1% of the company's shares are sold short.

Who are some of Gilead Sciences' key competitors?

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

  • John C. Martin Ph.D., Executive Chairman of the Board
  • John F. Milligan Ph.D., Chief Executive Officer, Director
  • Robin L. Washington, Chief Financial Officer, Executive Vice President
  • Kevin B. Young, Chief Operating Officer
  • Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
  • Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs
  • James R. Meyers, Executive Vice President - Worldwide Commercial Operations
  • John F. Cogan Jr. Ph.D., Lead Independent Director
  • Kelly A. Kramer, Independent Director
  • Kevin E. Lofton, Independent Director

Who owns Gilead Sciences stock?

Gilead Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include APG Asset Management N.V. (0.42%), State Treasurer State of Michigan (0.24%), Swedbank (0.17%), Chevy Chase Trust Holdings Inc. (0.09%), ANTIPODES PARTNERS Ltd (0.08%) and US Bancorp DE (0.08%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., NN Investment Partners Holdings N.V., First Quadrant L P CA, Beech Hill Advisors Inc., TNB Financial, Sit Investment Associates Inc., Trust Department MB Financial Bank N A and Exxonmobil Investment Management Inc. TX. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton and Paul Rutherford Carter. View Insider Buying and Selling for Gilead Sciences.

Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?

Gilead Sciences' stock was bought by a variety of institutional investors in the last quarter, including ANTIPODES PARTNERS Ltd, Aperio Group LLC, Foundation Resource Management Inc., Manning & Napier Advisors LLC, Mn Services Vermogensbeheer B.V., US Bancorp DE, National Pension Service and Exane Asset Management. View Insider Buying and Selling for Gilead Sciences.

How do I buy Gilead Sciences stock?

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of Gilead Sciences stock can currently be purchased for approximately $73.76.


MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  1,501 (Vote Outperform)
Underperform Votes:  485 (Vote Underperform)
Total Votes:  1,986
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 11 Hold Ratings, 14 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.62)
Consensus Price Target: $80.32 (8.90% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017BMO Capital MarketsReiterated RatingHold$72.00N/AView Rating Details
7/13/2017Robert W. BairdReiterated RatingOutperform$87.00LowView Rating Details
7/11/2017Morgan StanleyReiterated RatingEqual WeightLowView Rating Details
7/11/2017Jefferies Group LLCReiterated RatingHold -> Hold$80.00LowView Rating Details
7/5/2017Cowen and CompanyReiterated RatingOutperform$90.00LowView Rating Details
7/4/2017J P Morgan Chase & CoReiterated RatingOverweight$82.00LowView Rating Details
6/23/2017Deutsche Bank AGInitiated CoverageBuy$79.00LowView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
6/16/2017William BlairReiterated RatingOutperformLowView Rating Details
5/15/2017Credit Suisse Group AGReiterated RatingOutperform$79.00N/AView Rating Details
5/3/2017GabelliReiterated RatingBuy$85.00MediumView Rating Details
5/3/2017Barclays PLCReiterated RatingOverweight$85.00MediumView Rating Details
5/3/2017Stifel NicolausReiterated RatingBuy$87.00MediumView Rating Details
5/3/2017Maxim GroupReiterated RatingHoldLowView Rating Details
4/21/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
3/13/2017Bank of America CorporationReiterated RatingNeutral$76.00 -> $68.19LowView Rating Details
3/13/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$70.00 -> $68.00LowView Rating Details
3/1/2017MizuhoLower Price TargetBuy$88.00 -> $77.00N/AView Rating Details
2/14/2017Berenberg BankSet Price TargetBuy$112.00 -> $78.00N/AView Rating Details
2/8/2017Royal Bank Of CanadaLower Price Target$75.00N/AView Rating Details
2/8/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/8/2017Citigroup Inc.DowngradeBuy -> Neutral$87.00 -> $76.00N/AView Rating Details
2/8/2017Wells Fargo & CompanyReiterated RatingMarket Perform$79.50 -> $65.50N/AView Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00N/AView Rating Details
7/29/2016ArgusDowngradeBuy -> Hold$88.00 -> $81.00N/AView Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyN/AView Rating Details
5/4/2016Oppenheimer Holdings, Inc.Reiterated RatingBuy$120.00 -> $116.00N/AView Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00N/AView Rating Details
9/10/2015Jyske BankUpgradeStrong-Buy$125.00N/AView Rating Details
(Data available from 7/22/2015 forward)

Earnings

Earnings History for Gilead Sciences (NASDAQ:GILD)
Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)
Earnings History by Quarter for Gilead Sciences (NASDAQ GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 2017$2.18$2.20$6.66 billion$6.51 billionViewListenView Earnings Details
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.78$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.27$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.61$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.75$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
2017 EPS Consensus Estimate: $8.27
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$2.09$2.42$2.23
Q2 20173$2.01$2.29$2.15
Q3 20173$1.88$2.15$1.99
Q4 20173$1.79$2.09$1.91
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Gilead Sciences (NASDAQ:GILD)
Most Recent Dividend:6/29/2017
Annual Dividend:$2.08
Dividend Yield:2.82%
Payout Ratio:21.99% (Trailing 12 Months of Earnings)
26.07% (Based on This Year's Estimates)
28.97% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Dividend History by Quarter for Gilead Sciences (NASDAQ GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2017quarterly$0.523.09%6/14/20176/16/20176/29/2017
2/7/2017quarterly$0.523.11%3/14/20173/16/20173/30/2017
11/1/2016quarterly$0.472.59%12/13/201612/15/201612/29/2016
7/25/2016quarterly$0.472.32%9/14/20169/16/20169/29/2016
4/28/2016quarterly$0.472.13%6/14/20166/16/20166/29/2016
2/2/2016quarterly$0.431.99%3/14/20163/16/20163/30/2016
10/27/2015quarterly$0.431.59%12/14/201512/16/201512/30/2015
7/28/2015quarterly$0.431.49%9/14/20159/16/20159/29/2015
4/30/2015quarterly$0.436/12/20156/16/20156/29/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Gilead Sciences (NASDAQ:GILD)
Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 74.03%
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/3/2017Gregg H AltonEVPSell5,000$71.06$355,300.00View SEC Filing  
7/3/2017John C MartinInsiderSell73,333$71.00$5,206,643.00View SEC Filing  
5/9/2017John Francis CoganDirectorSell9,943$67.25$668,666.75View SEC Filing  
4/3/2017John C MartinInsiderSell73,333$67.18$4,926,510.94View SEC Filing  
3/30/2017Gregg H AltonEVPSell5,000$67.48$337,400.00View SEC Filing  
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.83View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.00View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.00View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.00View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.00View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.00View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Gilead Sciences (NASDAQ:GILD)
Latest Headlines for Gilead Sciences (NASDAQ:GILD)
Source:
DateHeadline
fool.com logoBetter Buy: Celgene Corporation vs. Gilead Sciences, Inc.
www.fool.com - July 22 at 11:55 AM
americanbankingnews.com logoBMO Capital Markets Reaffirms "Hold" Rating for Gilead Sciences, Inc. (NASDAQ:GILD)
www.americanbankingnews.com - July 22 at 11:34 AM
barrons.com logoWill Gilead Beat 2Q Earnings? Perhaps…But Does It Matter? - Barron's
www.barrons.com - July 22 at 12:24 AM
seekingalpha.com logoTake Profits On Gilead - Seeking Alpha
seekingalpha.com - July 20 at 4:51 PM
finance.yahoo.com logoIs Gilead (GILD) Poised for a Beat This Earnings Season?
finance.yahoo.com - July 20 at 4:51 PM
finance.yahoo.com logoBiotech Bulletin of the Week: Gilead Sciences, Inc. (GILD), Vertex Pharmaceuticals Incorporated (VRTX), and Keryx Biopharmaceuticals (KERX)
finance.yahoo.com - July 20 at 4:51 PM
finance.yahoo.com logoVertex Becomes an Overnight Biotech M&A Darling
finance.yahoo.com - July 20 at 4:51 PM
finance.yahoo.com logoWhen It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
finance.yahoo.com - July 20 at 12:46 AM
seekingalpha.com logoGilead Sciences' Shares Just Answered The Question - Seeking Alpha
seekingalpha.com - July 19 at 7:43 PM
americanbankingnews.com logoQ4 2017 Earnings Estimate for Gilead Sciences, Inc. (GILD) Issued By Leerink Swann
www.americanbankingnews.com - July 19 at 12:21 PM
streetinsider.com logoGilead Sciences (GILD) Vosevi Approved by FDA; Has Black Box Warning on Risk of HBV Reactivation
www.streetinsider.com - July 19 at 1:35 AM
nasdaq.com logoAgree To Purchase Gilead Sciences At $40, Earn 2.5% Using Options
www.nasdaq.com - July 19 at 1:35 AM
finance.yahoo.com logoU.S. Food and Drug Administration Approves Gilead’s Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus
finance.yahoo.com - July 19 at 1:35 AM
finance.yahoo.com logoGilead Secures FDA Approval For Chronic Hepatitis C Re-Treatment
finance.yahoo.com - July 19 at 1:35 AM
finance.yahoo.com logoFDA approves Gilead's drug for chronic hep C patients
finance.yahoo.com - July 19 at 1:35 AM
marketwatch.com logoVertex shares soar 24% to all-time high on cystic fibrosis drug studies - MarketWatch
www.marketwatch.com - July 18 at 8:33 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Gilead Sciences, Inc. (NASDAQ:GILD) Increased by Analyst
www.americanbankingnews.com - July 18 at 9:21 AM
fool.com logo5 Ways Gilead Sciences Could Spend Its Cash Hoard
www.fool.com - July 18 at 8:46 AM
seekingalpha.com logo9 Reasons Gilead Will Not Acquire Incyte - Seeking Alpha
seekingalpha.com - July 17 at 7:57 PM
americanbankingnews.com logoGilead Sciences, Inc. (NASDAQ:GILD) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - July 17 at 3:28 PM
finance.yahoo.com logoWill the Drug Pricing Executive Order Help Big Pharma?
finance.yahoo.com - July 17 at 11:47 AM
finance.yahoo.com logoHow Intangible Assets Create Value
finance.yahoo.com - July 17 at 11:47 AM
finance.yahoo.com logoThese 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition
finance.yahoo.com - July 16 at 6:09 PM
finance.yahoo.com logoGilead (GILD) Application for HIV Drug Validated in EU - Yahoo Finance
finance.yahoo.com - July 16 at 11:01 AM
americanbankingnews.com logoGilead Sciences, Inc. (NASDAQ:GILD) Expected to Announce Quarterly Sales of $6.35 Billion
www.americanbankingnews.com - July 15 at 8:04 AM
americanbankingnews.com logoShort Interest in Gilead Sciences, Inc. (GILD) Expands By 15.7%
www.americanbankingnews.com - July 15 at 7:22 AM
finance.yahoo.com logo[$$] "A Great Time" to Invest in the Health-Care Sector
finance.yahoo.com - July 15 at 1:03 AM
barrons.com logoThe Acquisition That Could Put Gilead Over $100 - Barron's
www.barrons.com - July 14 at 7:57 PM
finance.yahoo.com logoEuropean Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
finance.yahoo.com - July 13 at 10:31 PM
americanbankingnews.com logoRobert W. Baird Reiterates "Outperform" Rating for Gilead Sciences, Inc. (NASDAQ:GILD)
www.americanbankingnews.com - July 13 at 8:28 PM
americanbankingnews.com logoGilead Sciences, Inc. (NASDAQ:GILD) Expected to Post Earnings of $2.08 Per Share
www.americanbankingnews.com - July 13 at 6:30 PM
seekingalpha.com logoAnother Reason To Buy Gilead - Seeking Alpha
seekingalpha.com - July 13 at 4:15 PM
finance.yahoo.com logo5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates
finance.yahoo.com - July 13 at 4:15 PM
americanbankingnews.com logoBrokers Offer Predictions for Gilead Sciences, Inc.'s Q2 2017 Earnings (NASDAQ:GILD)
www.americanbankingnews.com - July 13 at 10:00 AM
finance.yahoo.com logoGilead Sciences to Release Second Quarter 2017 Financial Results on Wednesday, July 26, 2017
finance.yahoo.com - July 12 at 7:44 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms Hold Rating for Gilead Sciences, Inc. (NASDAQ:GILD)
www.americanbankingnews.com - July 11 at 8:59 AM
finance.yahoo.com logoA Look at Gilead Sciences Stock in 2Q17
finance.yahoo.com - July 10 at 6:58 PM
americanbankingnews.com logoGilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 10 at 12:49 PM
fool.com logoHow Shrewd of a Dealmaker Is Gilead Sciences? Just Look at Its Last 7 Acquisitions
www.fool.com - July 9 at 11:21 AM
finance.yahoo.com logoWill Gilead's Dividend Keep Climbing?
finance.yahoo.com - July 8 at 11:05 AM
finance.yahoo.com logoAre Gilead's Fortunes About To Change — Without An Acquisition?
finance.yahoo.com - July 8 at 11:05 AM
finance.yahoo.com logoWhat's Behind Gilead Sciences, Inc.'s 9.5% Rally in June
finance.yahoo.com - July 8 at 11:05 AM
fool.com logoWhat's Behind Gilead Sciences, Inc.'s 9.5% Rally in June
www.fool.com - July 7 at 7:26 PM
nasdaq.com logoGILD Dividend Yield Pushes Past 3%
www.nasdaq.com - July 6 at 8:57 PM
americanbankingnews.com logoGregg H. Alton Sells 5,000 Shares of Gilead Sciences, Inc. (GILD) Stock
www.americanbankingnews.com - July 6 at 7:40 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Insider Sells $5,206,643.00 in Stock
www.americanbankingnews.com - July 6 at 7:22 PM
nasdaq.com logoGalapagos-Gilead Begin Phase II Study on Uveitis Candidate - Nasdaq
www.nasdaq.com - July 5 at 7:41 PM
marketwatch.com logoFund manager profited from tech, says now is time to focus on health-care sector - MarketWatch
www.marketwatch.com - July 5 at 7:41 PM
investorplace.com logoBank on Gilead Sciences, Inc. (GILD) Stock Getting Its Mojo Back - Investorplace.com
investorplace.com - July 5 at 7:41 PM
finance.yahoo.com logoGalapagos-Gilead Begin Phase II Study on Uveitis Candidate
finance.yahoo.com - July 5 at 7:41 PM

Social

Chart

Gilead Sciences (GILD) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by MarketBeat.com Staff